Article
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size.
International journal of cancer - 1 Aug 2012
Capper David, Simon Matthias, Langhans Claus-Dieter, Okun Jürgen G, Tonn Jörg C, Weller Michael, von Deimling Andreas, Hartmann Christian
Abstract excerpt
IDH1/2 mutations occur at high frequency in diffusely infiltrating gliomas of the WHO grades II and III and were identified as a strong prognostic marker in all WHO grades of gliomas. Mutated IDH1 or IDH2 protein leads to the generation of excessive amounts of the metabolite 2-hydroxyglutarate (2HG) in tumor cells. Here, we evaluated whether 2HG levels in preoperative serum samples from patients with gliomas...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
